Settlements between originators and generics can benefit consumers, claims research
A recent study claims that US consumers and the federal government have saved around $25.5 billion on the cost of drugs since 2005 due to patent dispute settlements between pharmaceutical originators and generic manufacturers. While ‘pay-for-delay’…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now